Back to Search Start Over

Senhwa Biosciences seeks US FDA and Health Canada approvals for CX-5461 to treat solid tumors with BRCA2 or PALB2 mutations

Source :
PharmaBiz. November 27, 2020
Publication Year :
2020

Abstract

Senhwa Biosciences Inc, a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, announced that it has submitted multiple Investigational New Drug (IND) [...]

Subjects

Subjects :
United States. Food and Drug Administration
Cancer treatment
Talazoparib
Cancer research -- Genetic aspects
Tumors -- Drug therapy -- Genetic aspects
Drug approval
Pharmaceuticals and cosmetics industries

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.642974374

Tools

Authors Abstract Subjects Details